Burford Brothers Inc. Invests $817,000 in Sanofi $SNY

Burford Brothers Inc. acquired a new stake in shares of Sanofi (NASDAQ:SNY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 16,914 shares of the company’s stock, valued at approximately $817,000.

Several other large investors also recently bought and sold shares of SNY. Brighton Jones LLC lifted its stake in Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares during the period. GAMMA Investing LLC boosted its holdings in Sanofi by 58.7% in the first quarter. GAMMA Investing LLC now owns 6,057 shares of the company’s stock worth $336,000 after purchasing an additional 2,241 shares during the last quarter. Sowell Financial Services LLC bought a new stake in Sanofi in the 1st quarter worth approximately $328,000. ORG Wealth Partners LLC purchased a new stake in Sanofi during the 1st quarter valued at $91,000. Finally, Blue Trust Inc. lifted its holdings in shares of Sanofi by 38.9% during the 1st quarter. Blue Trust Inc. now owns 16,806 shares of the company’s stock valued at $932,000 after buying an additional 4,708 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on SNY. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a report on Wednesday, October 8th. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Barclays restated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Finally, Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Sanofi presently has an average rating of “Buy” and a consensus price target of $62.67.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $50.62 on Friday. The company has a market cap of $124.30 billion, a P/E ratio of 12.17, a P/E/G ratio of 1.23 and a beta of 0.51. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The firm’s fifty day moving average is $48.49 and its two-hundred day moving average is $49.60.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period last year, the firm posted $1.73 earnings per share. As a group, analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.